The parallel, time-dependent, bimodal change in lymphocyte cholinergic binding activity and cholinergic influence upon lymphocyte-mediated cytotoxicity after lymphocyte activation.
The potent muscarinic cholinergic antagonist 3-quinuclidinyl benzilate has been used to detect muscarinic acetylcholine receptors on rodent and human lymphocytes. Binding to B lymphocytes was minimal and was not saturable or ligand specific. Half-maximal binding of (3H)-quinuclidinyl benzilate to T lymphocytes occurred at concentrations comparable to those described in other systems, and was displaceable at physiologic concentrations by muscarinic but not nicotinic agonists and antagonists. Binding to T lymphocytes was both saturable and specific, and was found to rapidly increase significantly after mitogen activation. Activation of T lymphocytes or the Lyt 1+ subset produces an early increase and later fall in muscarinic binding, and the ability od cholinergic agonists to augment the effector function of cytotoxic T lymphocytes harvested from alloimmune rat spleen is directly related to the magnitude of muscarinic binding.
D000818:Animals; D001402:B-Lymphocytes / Q000378:metabolism; D002642:Chick Embryo; D003602:Cytotoxicity, Immunologic; D006801:Humans; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000378:metabolism*; D011813:Quinuclidinyl Benzilate / Q000494:pharmacology; D051381:Rats; D011948:Receptors, Antigen, T-Cell; D011950:Receptors, Cholinergic; D011955:Receptors, Drug; D016038:Skin Transplantation; D013601:T-Lymphocytes / Q000378:metabolism; D013997:Time Factors
D011948:Receptors, Antigen, T-Cell; D011950:Receptors, Cholinergic; D011955:Receptors, Drug; D011813:Quinuclidinyl Benzilate